title: [Combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF), and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)].
abstract: We evaluated the recommend dose and efficacy of chemotherapy (CTx) and concurrent chemoradiotherapy (ConcCRTx) with docetaxel (DOC), cisplatin (CDDP) and 5-FU (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Patients underwent 2 cycles of chemotherapy with TPF. In ConcCRTx, radiation was targeted to begin on Day 1. We compared the efficacy of ConcCRTx and induction chemotherapy followed by radiation (CTx followed by RTx) with TPF. In CTx followed by RTx, radiation was targeted to begin 21 days after the end of CTx. The recommend dose of CTx with TPF was DOC 60 (Day 1), CDDP 70 (Day 4) and 5 FU 750 (Day 1-5) mg/ m2/ day and overall response rate of CTx with TPF was 95%. The recommended dose of ConcCRTx was DOC 50 (Day 1), CDDP 60 (Day 4) and 5-FU 600 (Day 1-5) mg/ m2/ day. Overall response rate of ConcCRTx and CTx followed by RTx with TPF were both 100%, and CR rate of them were 87% and 84% (p > 0.05). One-year survival rate of them were 69% and 95% (p < 0.05). More patients had distant metastasis in CTx followed by RTx than in ConcCRTx. Toxicity, such as mucositis, leukocytopenia and neutropenia, was higher in ConcCRTx than in CTx followed by RTx.
authors.affiliation: Department of Otolaryngology, Yokohama City University Medical Center, Yokohama.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Katori
authors.forename: Mamoru
authors.initials: M
authors.lastname: Tsukuda
authors.forename: Junichi
authors.initials: J
authors.lastname: Ishitoya
authors.forename: Yasukazu
authors.initials: Y
authors.lastname: Mikami
authors.forename: Hideki
authors.initials: H
authors.lastname: Matsuda
authors.forename: Yuji
authors.initials: Y
authors.lastname: Tanigaki
authors.forename: Chouichi
authors.initials: C
authors.lastname: Horiuchi
authors.forename: Youichi
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Machiko
authors.initials: M
authors.lastname: Kimura
authors.forename: Takahide
authors.initials: T
authors.lastname: Taguchi
authors.forename: Shouji
authors.initials: S
authors.lastname: Hirose
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshida
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takahashi
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Sakuma
authors.forename: Kaoru
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Nao
authors.initials: N
authors.lastname: Sato
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D000077143:Docetaxel; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D005472:Fluorouracil